


PRODUCT INFORMATION



Erythromyclamine

Item No. 28098

CAS Registry No.: 26116-56-3
Formal Name: (9S)-9-amino-9-deoxy-erythromycin
Synonyms: BRL 42852ER, 9(S)-Erythromyclamine, LY024410
MF: C₃₇H₇₀N₂O₁₂
FW: 735.0
Purity: ≥95%
UV/Vis.: λ_{max}: 269 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Erythromyclamine is supplied as a solid. A stock solution may be made by dissolving the erythromyclamine in the solvent of choice, which should be purged with an inert gas. Erythromyclamine is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of erythromyclamine in ethanol is approximately 30 mg/ml and approximately 15 mg/ml in DMSO and DMF.

Erythromyclamine is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, erythromyclamine should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Erythromyclamine has a solubility of approximately 0.5 mg/ml in a 1:1 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Erythromyclamine is a macrolide antibiotic and an active metabolite of dirithromycin (Item No. 19466).¹ It is active against a variety of bacteria, including strains of *S. pyogenes*, *S. pneumoniae*, *L. monocytogenes*, and *B. pertussis* (MICs = 0.06-0.12, 0.06-0.12, 1-2, and 0.015-0.25 µg/ml, respectively). It is also active against 28 clinical isolates of *M. avium* complex (MAC) isolated from patients with AIDS (MICs = 4-16 µg/ml).² Erythromyclamine inhibits polylysine and polyproline synthesis in a cell-free assay.³

References

1. Hardy, D.J., Hensey, D.M., Beyer, J.M., *et al.* Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. *Antimicrob. Agents Chemother.* **32(11)**, 1710-1719 (1988).
2. Naik, S. and Ruck, R. In vitro activities of several new macrolide antibiotics against *Mycobacterium avium* complex. *Antimicrob. Agents Chemother.* **33(9)**, 1614-1616 (1989).
3. Matijašević, P., Franjić, N., Đokić, S., *et al.* Erythromycin series. X. Inhibitory activity of several new erythromycin derivatives in cell-free amino acid polymerization systems. *Croat. Chem. Acta* **53(3)**, 519-524 (1980).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/02/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM